Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.

Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S, Piccini P.

J Clin Invest. 2014 Mar;124(3):1340-9. doi: 10.1172/JCI71640. Epub 2014 Feb 17.

2.

Molecular imaging of levodopa-induced dyskinesias.

Niccolini F, Rocchi L, Politis M.

Cell Mol Life Sci. 2015 Jun;72(11):2107-17. doi: 10.1007/s00018-015-1854-x. Epub 2015 Feb 15. Review.

PMID:
25681866
3.

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.

de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ.

Brain. 2004 Dec;127(Pt 12):2747-54. Epub 2004 Aug 25.

PMID:
15329355
4.

The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study.

Smith R, Wu K, Hart T, Loane C, Brooks DJ, Björklund A, Odin P, Piccini P, Politis M.

Neurobiol Aging. 2015 Apr;36(4):1736-42. doi: 10.1016/j.neurobiolaging.2014.12.037. Epub 2015 Jan 6.

PMID:
25649022
5.

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Långström B.

Neurology. 1996 May;46(5):1430-6.

PMID:
8628494
6.

Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.

Cheshire P, Ayton S, Bertram KL, Ling H, Li A, McLean C, Halliday GM, O'Sullivan SS, Revesz T, Finkelstein DI, Storey E, Williams DR.

Mov Disord. 2015 May;30(6):796-804. doi: 10.1002/mds.26144. Epub 2015 Feb 4.

PMID:
25649148
7.

Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.

Shin E, Garcia J, Winkler C, Björklund A, Carta M.

Neurobiol Dis. 2012 Sep;47(3):393-406. doi: 10.1016/j.nbd.2012.03.038. Epub 2012 Apr 12.

PMID:
22579773
8.

Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.

Nahimi A, Høltzermann M, Landau AM, Simonsen M, Jakobsen S, Alstrup AK, Vang K, Møller A, Wegener G, Gjedde A, Doudet DJ.

J Neurochem. 2012 Mar;120(5):806-17. doi: 10.1111/j.1471-4159.2011.07598.x. Epub 2012 Jan 23.

9.

Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.

Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y.

Brain. 2008 Jan;131(Pt 1):120-31. Epub 2007 Oct 22.

PMID:
17956909
10.

Dyskinesias in Parkinson's disease: views from positron emission tomography studies.

Niccolini F, Loane C, Politis M.

Eur J Neurol. 2014 May;21(5):694-9, e39-43. doi: 10.1111/ene.12362. Epub 2014 Jan 28. Review.

PMID:
24471508
11.

Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.

Roussakis AA, Politis M, Towey D, Piccini P.

Neurology. 2016 Mar 22;86(12):1152-8. doi: 10.1212/WNL.0000000000002494. Epub 2016 Feb 26.

PMID:
26920358
12.

Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.

Neuropharmacology. 2015 Jun;93:52-67. doi: 10.1016/j.neuropharm.2015.01.012. Epub 2015 Jan 31.

PMID:
25645393
13.

Buspirone in levodopa-induced dyskinesias.

Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G.

Clin Neuropharmacol. 1994 Feb;17(1):73-82.

PMID:
8149361
14.

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.

Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ.

Neurology. 2011 May 24;76(21):1811-6. doi: 10.1212/WNL.0b013e31821ccce4.

15.

Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.

Azkona G, Sagarduy A, Aristieta A, Vazquez N, Zubillaga V, Ruíz-Ortega JA, Pérez-Navarro E, Ugedo L, Sánchez-Pernaute R.

Neuropharmacology. 2014 Apr;79:726-37. doi: 10.1016/j.neuropharm.2013.11.024. Epub 2013 Dec 10.

PMID:
24333147
16.

Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.

Tani Y, Ogata A, Koyama M, Inoue T.

Eur J Pharmacol. 2010 Dec 15;649(1-3):218-23. doi: 10.1016/j.ejphar.2010.09.013. Epub 2010 Sep 19.

PMID:
20858480
17.

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL; PKDS009 Study Group.

CNS Drugs. 2004;18(11):733-46. Erratum in: CNS Drugs. 2005;19(7):633.

PMID:
15330687
18.
19.

Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.

Lindenbach D, Palumbo N, Ostock CY, Vilceus N, Conti MM, Bishop C.

Br J Pharmacol. 2015 Jan;172(1):119-30. doi: 10.1111/bph.12894. Epub 2014 Nov 24.

20.

Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease.

Brusa L, Orlacchio A, Stefani A, Galati S, Pierantozzi M, Iani C, Mercuri NB.

Funct Neurol. 2013 Apr-May;28(2):101-5. doi: 10.11138/FNeur/2013.28.2.101.

Supplemental Content

Support Center